POSTERS ASCO 2024

Cáncer ginecológico

Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Abstract: 5531 Poster Bd #: 402

Poster

Descargar

Autor
Luis Manso, MD

Hospital Universitario 12 de Octubre and GEICO

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON